pp-180 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Post-essential thrombocythemia myelofibrosis (Post-ET MF); post-polycythaemia vera MF (Post-PV MF); atopic dermatitis; alopecia areata
Clinical stage: Phase 3 — multiple trials ongoing in China
Modality: Small molecule (oral tablet; topical cream formulation)
Mechanism / Target: Pan-JAK inhibitor (JAK1, JAK2, JAK3) — blocks JAK-STAT cytokine signalling; reduces splenomegaly and constitutional symptoms in MF; inhibits Th2/Th17 cytokine axes in atopic dermatitis
Route / form: Oral tablet (MF, AD); topical cream (AD)
Differentiation: Broad JAK1/2/3 coverage may provide deeper cytokine suppression; topical formulation for AD differentiates from systemic JAK inhibitors; multiple indications expanding addressable market
Manufacturer #39198
Clinical-stage biopharmaceutical company specialising in JAK inhibitors for haematological and inflammatory diseases. Develops oral and topical JAK pathway inhibitors across multiple indications in China. Wholly owned Phase 3 pipeline spanning myelofibrosis, dermatitis and alopecia.
None